Forum Archive Index - May 2000

[Brett & Leeanne Phillips <bret-lil@ihug.co.nz>]

Hi everyone, 

Just a quick note to follow up on the Revesco postings by Osbert and myself
last week.

Along with Salomon Smith Barney and BNP Equities Research rating Revesco as
a buy around the 40 cent(Aust) in their latest market reports, I note  that
David McEwen is also recommending the stock in his latest sharechat
interview. Suggest you check out the Q&A.

He comments on the limited to medium risk at the current market price
because RVS is specialising in niche medical technology. Also the medical
sector must surely grow further as the baby boomers age and require the
services that are now becoming available. These services require specialist
knowledge, expertise and will generally return high margins.

I suggest Revesco may also gain investor interest through their latest
acquisitions Gribbles Pathology , when and if a buyer is confirmed for Mayne
Nickless. This confirmation will encourage others to also seek the returns
that Institutional funds have already foreseen.

Cheers Brett   







----------------------------------------------------------------------------
http://www.sharechat.co.nz/          New Zealand's home for market investors
To remove yourself from this list, please us the form at
http://www.sharechat.co.nz/forum.html.